Citations

Mayo Clinic

Showing 10 of 108522 citations.

Spontaneous Coronary Artery Dissection
Eleid, Mackram F. , Best, Patricia J.M. , Lennon, Ryan J. , Rihal, Charanjit S. , Holmes, David R. , Gulati, Rajiv , Tweet, Marysia S. , Lennon, Ryan J. , Lerman, Amir , Rihal, Charanjit S. , Hayes, Sharonne N.

Circulation: Cardiovascular Interventions | November 18, 2014 | Volume: 7 | Issue: 6 | Pages: 777-786

10.1161/circinterventions.114.001659 | PMID 25406203 Get It

Background— Spontaneous coronary artery dissection (SCAD) is a nonatherosclerotic acute coronary syndrome for which optimal management remains undefined. Methods and Results— We performed a retrospective study of 189 patients presenting with a first SCAD episode. We evaluated outcomes according to initial management: (1) revascularization versus conservative therapy and (2) percutaneous coronary intervention (PCI) versus conservative therapy stratified by vessel flow at presentation. Demographics were similar in revascularization versus conservative (mean age, 44±9 years; women 92% both groups), but vessel occlusion was more frequent in revascularization (44/95 versus 18/94). There was 1 in-hospital death (revascularization) and 1 late death (conservative). Procedural failure rate was 53% in those managed with PCI. In the subgroup of patients presenting with preserved vessel flow, rates of PCI failure were similarly high (50%), and 6 (13%) required emergency coronary artery bypass grafting. In the conservative group, 85 of 94 (90%) had an uneventful in-hospital course, but 9 (10%) experienced early SCAD progression requiring revascularization. Kaplan–Meier estimated 5-year rates of target vessel revascularization and recurrent SCAD were no different in revascularization versus conservative therapy (30% versus 19%; P =0.06 and 23% versus 31%; P =0.7). Conclusions— PCI for SCAD is associated with high rates of technical failure even in those presenting with preserved vessel flow and does not protect against target vessel revascularization or recurrent SCAD. A strategy of conservative management with prolonged observation may be preferable.
Mitochondria
Eirin, Alfonso , Lerman, Lilach O. , Lerman, Amir , Eirin, Alfonso

Hypertension | November 18, 2014 | Volume: 65 | Issue: 2 | Pages: 264-270

10.1161/hypertensionaha.114.04598 | PMID 25403611 Get It

Evaluation of the National Comprehensive Cancer Network and American Urological Association Renal Cell Carcinoma Surveillance Guidelines
Stewart, Suzanne, Thompson, R. Houston, Psutka, Sarah P. , Cheville, John C. , Lohse, Christine M. , Boorjian, Stephen A. , Leibovich, Bradley C. , Stewart, Suzanne B, Psutka, Sarah P

Journal of Clinical Oncology | November 18, 2014 | Volume: 32 | Issue: 36 | Pages: 4059-4065

10.1200/jco.2014.56.5416 | PMID 25403213 Get It

Purpose The National Comprehensive Cancer Network (NCCN) and American Urological Association (AUA) provide guidelines for surveillance after surgery for renal cell carcinoma (RCC). Herein, we assess the ability of the guidelines to capture RCC recurrences and determine the duration of surveillance required to capture 90%, 95%, and 100% of recurrences. Patients and Methods We evaluated 3,651 patients who underwent surgery for M0 RCC between 1970 and 2008. Patients were stratified as AUA low risk (pT1Nx-0) after partial (LR-partial) or radical nephrectomy (LR-radical) or as moderate/high risk (M/HR; pT2-4Nx-0/pTanyN1). Guidelines were assessed by calculating the percentage of recurrences detected when following the 2013 and 2014 NCCN and AUA recommendations, and associated Medicare costs were compared. Results At a median follow-up of 9.0 years (interquartile range, 5.7 to 14.4 years), a total of 1,088 patients (29.8%) experienced a recurrence. Of these, 390 recurrences (35.9%) were detected using 2013 NCCN recommendations, 742 recurrences (68.2%) were detected using 2014 NCCN recommendations, and 728 recurrences (66.9%) were detected using AUA recommendations. All protocols missed the greatest amount of recurrences in the abdomen and among pT1Nx-0 patients. To capture 95% of recurrences, surveillance was required for 15 years for LR-partial, 21 years for LR-radical, and 14 years for M/HR patients. Medicare surveillance costs for one LR-partial patient were $1,228.79 using 2013 NCCN, $2,131.52 using 2014 NCCN, and $1,738.31 using AUA guidelines. However, if 95% of LR-partial recurrences were captured, costs would total $9,856.82. Conclusion If strictly followed, the 2014 NCCN and AUA guidelines will miss approximately one third of RCC recurrences. Improved surveillance algorithms, which balance patient benefits and health care costs, are needed.
Synchronous hepatic and splenic inflammatory pseudotumour‐like follicular dendritic cell sarcomas
Roarke, Michael C., Yang, Ming , Nguyen, Ba D.

Liver International | November 18, 2014 | Volume: 35 | Issue: 7 | Pages: 1917-1917

10.1111/liv.12738 | PMID 25404171 Get It

Comparison of Community Health Worker–Led Diabetes Medication Decision-Making Support for Low-Income Latino and African American Adults With Diabetes Using E-Health Tools Versus Print Materials
Heisler, Michele , Choi, HwaJung , Palmisano, Gloria , Mase, Rebecca, Richardson, Caroline R. , Montori, Víctor M. , Spencer, Michael S. , An, Laurence C., Fagerlin, Angela , Montori, Victor M

Annals of Internal Medicine | November 17, 2014 | Volume: 161 | Issue: 10_Supplement | Pages: S13-S22

10.7326/m13-3012 | PMID 25402398 Get It

The Media and Behavioral Genetics
Dingel, Molly J. , Ostergren, Jenny E., Hammer, Rachel, Koenig, Barbara A. , McCormick, Jennifer B, McCormick, Jennifer Blair

Science, Technology, & Human Values | November 17, 2014 | Volume: 40 | Issue: 4 | Pages: 459-486

10.1177/0162243914558491 | PMID 26392644 Get It

To understand public discourse in the United States on genetic causation of behavioral disorders, we analyzed media representations of genetic research on addiction published between 1990 and 2010. We conclude first that the media simplistically represent biological bases of addiction and willpower as being mutually exclusive: behaviors are either genetically determined, or they are a choice. Second, most articles provide only cursory or no treatment of the environmental contribution. A media focus on genetics directs attention away from environmental factors. Rhetorically, media neglect the complexity underlying the etiology the addiction and direct focus back toward individual causation and responsibility.
Optimal Medical Therapy vs CT Angiography Screening for Patients With Diabetes
Gibbons, Raymond J.

JAMA | November 17, 2014 | Volume: 312 | Issue: 21 | Pages: 2219

10.1001/jama.2014.15958 | PMID 25402605 Get It

Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation
Reece, Donna , Beksaç, Meral , Spencer, Andrew , Sonneveld, Pieter , Kalimi, Ghulam H., Shi, Michael, Scott, Jeffrey W., Stewart, A. Keith, Beksaç, Meral , Scheid, Christof , Callander, Natalie S. , Cai, Can , Beksac, Meral

European Journal of Haematology | November 17, 2014 | Volume: 95 | Issue: 4 | Pages: 316-324

10.1111/ejh.12491 | PMID 25402977 Get It

AbstractObjectivesApproximately 15% of patients with multiple myeloma (MM) exhibit a t(4;14) translocation, which often results in constitutive activation of the receptor tyrosine kinase (RTK) fibroblast growth factor receptor 3 (FGFR3). This study evaluated the efficacy and safety of dovitinib, an RTK inhibitor with in vitro inhibitory activity against FGFR, in patients with relapsed or refractory MM with or without t(4;14) translocation.MethodsAdult patients with relapsed or refractory MM who had received ≥2 prior regimens were enrolled in this multicenter, 2‐stage, phase 2 trial. Patients were grouped based on their t(4;14) status. Dovitinib (500 mg/day orally) was administered on a 5‐days‐on/2‐days‐off schedule. The primary endpoint was overall response rate by local investigator review (per International Myeloma Working Group criteria). In non‐responding patients, treatment could continue with the addition of low‐dose dexamethasone.ResultsIn total, 43 patients (median age, 63 years) were enrolled (13 t(4;14) positive, 26 t(4;14) negative, and 4 t(4;14) status non‐interpretable). Patients had received a median of 5 prior regimens. Median duration of treatment was 8.7 weeks in the t(4;14)‐positive group and 3.7 weeks in the t(4;14)‐negative group. None of the patients on dovitinib had objective responses. The stable disease rate was 61.5% in the t(4;14)‐positive group and 34.6% in the t(4;14)‐negative group. Overall, 39 patients (90.7%) had adverse events suspected to be related to study drug, most commonly diarrhea (60.5%), nausea (58.1%), vomiting (46.5%), and fatigue (32.6%).ConclusionDovitinib showed no single‐agent activity in relapsed or refractory MM but may stabilize disease in some t(4;14)‐positive patients.
The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer
Sanda, Martin G. , Broyles, Dennis L., Shin, Sanghyuk S. , Bangma, Chris H. , Wei, John T., Partin, Alan W. , Klee, George G., Slawin, Kevin M., Marks, Leonard S. , Schaik, Ron H. N. van , Chan, Daniel W. , Sokoll, Lori J. , Cruz, Amabelle B., Mizrahi, Isaac, Catàlona, William J. , Loeb, Stacy

Journal of Urology | November 17, 2014 | Volume: 193 | Issue: 4 | Pages: 1163-1169

10.1016/j.juro.2014.10.121 | PMID 25463993 Get It